References
- Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012 Jan;19(1):155–162.
- Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness–1991. Soc Psychiatry Psychiatr Epidemiol. 1995 Aug;30(5):213–219.
- Tse S, Chan S, Ng KL, et al. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 2014 May;16(3):217–229.
- Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychology. 2009 Sep;23(5):551–562.
- Rock PL, Roiser JP, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2013 Oct 29:1–12.
- Miskowiak KW, Carvalho AF, Vieta E, et al. Cognitive enhancement treatments for bipolar disorder: A systematic review and methodological recommendations. Eur Neuropsychopharmacol. 2016 Oct;26(10):1541–1561.
- Miskowiak KW, Ott CV, Petersen JZ, et al. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. Eur Neuropsychopharmacol. 2016 Dec;26(12):1845–1867.
- Canales-Rodriguez EJ, Pomarol-Clotet E, Radua J, et al. Structural abnormalities in bipolar Euthymia: a multicontrast molecular diffusion imaging study. Biol Psychiatry. 2014 Aug 1;76(3):239–248.
- McKinnon MC, Yucel K, Nazarov A, et al. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci. 2009 Jan;34(1):41–54.
- Marsden WN. Synaptic plasticity in depression: molecular, cellular and functional correlates. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun;3(43):168–184.
- Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006 Feb;7(2):137–151.
- Frodl T, Jager M, Smajstrlova I, et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci. 2008 Sep;33(5):423–430.
- Yucel K, Taylor VH, McKinnon MC, et al. Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology. 2008 Jan;33(2):361–367.
- Sargin D, Friedrichs H, El-Kordi A, et al. Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):573–594.
- Miskowiak K, O’Sullivan U, Harmer CJ. Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci. 2007 Mar 14;27(11):2788–2792.
- Miskowiak KW, Vinberg M, Christensen EM, et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology. 2014 May;39(6):1399–1408.
- Miskowiak KW, Ehrenreich H, Christensen EM, et al. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. J Clin Psychiatry. 2014 Dec;75(12):1347–1355.
- Ott CV, Vinberg M, Kessing LV, et al. The effect of erythropoietin on cognition in affective disorders - associations with baseline deficits and change in subjective cognitive complaints. Eur Neuropsychopharmacol. 2016 Aug;26(8):1264–1273.
- Miskowiak KW, Vinberg M, Macoveanu J, et al. Effects of Erythropoietin on hippocampal volume and memory in mood disorders. Biol Psychiatry. 2015 Aug 15;78(4):270–277.
- Jelkmann W, Bohlius J, Hallek M, et al. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008 Jul;67(1):39–61.